Current Report Filing (8-k)
June 08 2016 - 6:32AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): June 7, 2016
Amarin Corporation plc
(Exact name of registrant as specified in its charter)
|
|
|
|
|
England and Wales
|
|
0-21392
|
|
Not applicable
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
2 Pembroke House, Upper Pembroke Street 28-32,
Dublin 2, Ireland
|
|
Not applicable
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: +353 1 6699 020
Not Applicable
Former
name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 7.01 Regulation FD disclosure
On June 7, 2016, Watson Laboratories Inc. (Watson) filed a motion for voluntary dismissal with the United States Court of Appeals (case no.
2016-1596) requesting the court terminate its own appeal of the January 22, 2016, U.S. District Court for the District of New Jersey order of dismissal of the abbreviated new drug application, or ANDA, patent infringement litigation (case no.
14-CV-3259) related to Vascepa
®
(icosapent ethyl) capsules. The motion by Watson, to which Amarin has consented, follows the May 31, 2016, FDA grant of five-year, new chemical entity
exclusivity with respect to Vascepa. Once the Court of Appeals grants Watsons unopposed motion to dismiss the appeal, there will be no pending patent litigation related to Vascepa.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
Date: June 8, 2016
|
|
|
|
Amarin Corporation plc
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ John Thero
|
|
|
|
|
|
|
|
|
John Thero
President and Chief Executive
Officer
|
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Apr 2023 to Apr 2024